General Information
Version
11.3
Revision date
2022-11-10
Product name
NERTA CARNET JUMBO
1.2.1 Relevant identified uses
Oil separator contents (petrol separator contents) Title
Icons in SDS
Company Information
company name
Chiefs Australia
e-mail address of the competent person responsible for the Safety Data Sheet
office@chiefsaustralia.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H318
Hazard statements
Code
Statements
H318
Causes serious eye damage
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Causes serious eye damage.
2.2 Label elements
Labelling
Hazard pictograms
GHS05
Signal word
Danger
Contains
tetrasodium ethylene diamine tetraacetate; Fatty alcohol ethoxylated
Hazard statements
H318 - Causes serious eye damage.
Precautionary statements
P280 - Wear protective clothing, eye protection, face protection. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 - Immediately call a doctor, a POISON CENTER.
2.3 Other hazards
This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII Component Fatty alcohol ethoxylated (68439-50-9) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Quaternary ammonium compounds, C12-14- This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII alkyl(hydroxyethyl)dimethyl, ethoxylated, chlorides This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII (1554325-20-0) The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %